Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

epcoritamab-bsyp

epcoritamab-bsyp
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Epkinly INJECTION, INTRAVENOUS 4 mg/0.8 mL, 48 mg/0.8 mL      
Comments:

Restricted to oncology physician usage in the outpatient setting for the FDA approved indications. For required hospitalizations associated with step-up dosing, doses will be administered in outpatient bed in an inpatient monitoring area. Insurance/reimbursement evaluation to be done prior to starting this drug therapy.  May use as patient own medication through PAP.

 

 

 

 

 

Reviewed: November 2025         

Epcoritamab-bsyp (EPKINLY) Spotlight 10.2025 Update_Final.pdf     

Last updated: Dec. 18, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved